In: International Journal of Epidemiology, 2014, vol. 43, no. 3, p. 887-896
|
In: The Journal of Infectious Diseases, 2013, vol. 208, no. 7, p. 1102-1112
|
In: The Journal of Infectious Diseases, 2010, vol. 201, no. 12, p. 1788-1795
|
In: Journal of Antimicrobial Chemotherapy, 2009, vol. 64, no. 6, p. 1126-1129
|
In: International Journal of Epidemiology, 2012, vol. 41, no. 2, p. 433-445
|
In: Journal of Antimicrobial Chemotherapy, 2011, vol. 66, no. 9, p. 2107-2111
|
In: The Journal of Infectious Diseases, 2013, vol. 208, no. 9, p. 1454-1458
|
In: Clinical Infectious Diseases, 2010, vol. 50, no. 1, p. 115-118
|
In: The Journal of Infectious Diseases, 2014, vol. 210, no. 10, p. 1555-1561
|
In: Neurology, 2013, vol. 80, no. 6, p. 553–560
Objective: To assess the efficacy and safety of rivastigmine for the treatment of HIV-associated neurocognitive disorders (HAND) in a cohort of long-lasting aviremic HIV+ patients.Methods: Seventeen aviremic HIV+ patients with HAND were enrolled in a randomized, double-blind, placebo-controlled, crossover study to receive either oral rivastigmine (up to 12 mg/day for 20 weeks) followed by placebo...
|